nach oben

Erschienen in:

30.05.2016 | Original Article

Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells

verfasst von: Song Gao, Liancheng Zhu, Huilin Feng, Zhenhua Hu, Shan Jin, Zuofei Song, Dawo Liu, Juanjuan Liu, Yingying Hao, Xiao Li, Bei Lin

Erschienen in: Tumor Biology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to identify differentially expressed genes (DEGs) in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian cancer cells. Human whole-genome oligonucleotide microarrays were used to determine whether gene expression profile may differentiate the epithelial ovarian cell line Caov-3 transfected with FUT1 from the empty plasmid-transfected cells. Quantitative real-time PCR and immunohistochemical staining validated the microarray results. Gene expression profile identified 215 DEGs according to the selection criteria, in which 122 genes were upregulated and 93 genes were downregulated. Gene Ontology (GO) and canonical pathway enrichment analysis were applied, and we found that these DEGs are involved in BioCarta mammalian target of rapamycin (mTOR) pathway, BioCarta eukaryotic translation initiation factor 4 (EIF4) pathway, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in cancer. Interaction network analysis predicted genes participating in the regulatory connection. Highly differential expression of TRIM46, PCF11, BCL6, PTEN, and FUT1 genes was validated by quantitative real-time PCR in two cell line samples. Finally, BCL6 and Lewis Y antigen were validated at the protein level by immunohistochemistry in 103 paraffin-embedded ovarian cancer tissues. The identification of genes in response to FUT1 may provide a theoretical basis for the investigations of the molecular mechanism of ovarian cancer.

Nur mit Berechtigung zugänglich

Pliarchopoulou K, Pectasides D. Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2011;79:17–23.CrossRefPubMed

Iwamori M, Tanaka K, Kubushiro K, Lin B, Kiguchi K, Ishiwata I, Tsukazaki K, Nozawa S. Alterations in the glycolipid composition and cellular properties of ovarian carcinoma-derived RMG-1 cells on transfection of the alpha1,2-fucosyltransferase gene. Cancer Sci. 2005;96:26–30.CrossRefPubMed

Heimburg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse-Olson K. Cancer vaccines and carbohydrate epitopes. Vaccine. 2011;29:8802–26.CrossRefPubMedPubMedCentral

Fukuda M. Carbohydrate-dependent cell adhesion. Bioorg Med Chem. 1995;3:207–15.CrossRefPubMed

Yan LM, Lin B, Zhu LC, Hao YY, Qi Y, Wang CZ, Gao S, Liu SC, Zhang SL, Iwamori M. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie. 2010;92:852–7.CrossRefPubMed

Zhang F, Liu J, Lin B, Liu Q, Zhao Y, Zhu L, Hao Y, Zhang S, Iwamori M. Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen. Int J Mol Sci. 2011;12:7323–34.CrossRefPubMedPubMedCentral

Gao N, Liu J, Liu D, Hao Y, Yan L, Ma Y, Zhuang H, Hu Z, Gao J, Yang Z, Shi H, Lin B. c-Jun transcriptionally regulates alpha 1, 2-fucosyltransferase 1 (FUT1) in ovarian cancer. Biochimie. 2014;107(Pt B):286–92.CrossRefPubMed

Hu Z, Gao S, Gao J, Hou R, Liu C, Liu J, Li B, Liu D, Zhang S, Lin B. Elevated levels of Lewis y and integrin alpha5beta1 correlate with chemotherapeutic drug resistance in epithelial ovarian carcinoma. Int J Mol Sci. 2012;13:15588–600.CrossRefPubMedPubMedCentral

Gao J, Hu Z, Liu D, Liu J, Liu C, Hou R, Gao S, Zhang D, Zhang S, Lin B. Expression of Lewis y antigen and integrin alphav, beta3 in ovarian cancer and their relationship with chemotherapeutic drug resistance. J Exp Clin Cancer Res CR. 2013;32:36.CrossRefPubMed

10.

Hu Z, Gao J, Zhang D, Liu Q, Yan L, Gao L, Liu J, Liu D, Zhang S, Lin B. High expression of Lewis y antigen and CD44 is correlated with resistance to chemotherapy in epithelial ovarian cancers. PLoS One. 2013;8:e57250.CrossRefPubMedPubMedCentral

11.

Tan M, Zhu L, Zhuang H, Hao Y, Gao S, Liu S, Liu Q, Liu D, Liu J, Lin B. Lewis Y antigen modified CD47 is an independent risk factor for poor prognosis and promotes early ovarian cancer metastasis. Am J Cancer Res. 2015;5:2777–87.PubMedPubMedCentral

12.

Gao J, Hu Z, Liu J, Liu D, Wang Y, Cai M, Zhang D, Tan M, Lin B. Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance. Med Oncol. 2014;31:920.CrossRefPubMed

13.

Zhang D, Gao J, Zhu L, Hu Z, Hou R, Liu S, Tan M, Liu J, Lin B. Chemoresistance is associated with MUC1 and Lewis y antigen expression in ovarian epithelial cancers. Int J Mol Sci. 2013;14:11024–33.CrossRefPubMedPubMedCentral

14.

Wang H, Zhu L, Gao J, Hu Z, Lin B. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells. Oncol Rep. 2015;33:403–12.PubMed

15.

Zhu L, Gao J, Hu Z, Schwab C, Zhuang H, Tan M, Yan L, Liu J, Zhang D, Lin B. Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer. Am J Cancer Res. 2015;5:830–43.PubMedPubMedCentral

16.

Zhuang H, Tan M, Liu J, Li X, Gao J, Hu Z, Deng L, Zhu L, Lin B. The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015;36:2343–9.CrossRef

17.

Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY, Wang YF, Gao S, Qi Y, Zhang SL, Iwamori M. Expression and correlation of Lewis y antigen and TGF-beta1 in ovarian epithelial carcinoma. Oncol Rep. 2012;27:1065–71.PubMed

18.

Zhuang H, Hu Z, Tan M, Zhu L, Liu J, Liu D, Yan L, Lin B. Overexpression of Lewis y antigen promotes human epididymis protein 4-mediated invasion and metastasis of ovarian cancer cells. Biochimie. 2014;105:91–8.CrossRefPubMed

19.

Zhu L, Zhuang H, Wang H, Tan M, Schwab CL, Deng L, Gao J, Hao Y, Li X, Gao S, Liu J, Lin B. Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget. 2016;7:729–44.PubMed

20.

Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F, Liu D, Cong J, Zhang S, Iwamori M. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 2009;28:154.CrossRefPubMedPubMedCentral

21.

Liu D, Liu J, Wang C, Lin B, Liu Q, Hao Y, Zhang S, Iwamori M. The stimulation of IGF-1R expression by Lewis(y) antigen provides a powerful development mechanism of epithelial ovarian carcinoma. Int J Mol Sci. 2011;12:6781–95.CrossRefPubMedPubMedCentral

22.

Yan L, Wang C, Lin B, Liu J, Liu D, Hou R, Wang Y, Gao L, Zhang S, Iwamori M. Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 2015;113:17–25.CrossRefPubMed

23.

Li FF, Liu JJ, Liu DW, Lin B, Hao YY, Cong JP, Zhu LC, Gao S, Zhang SL, Iwamori M. Lewis Y regulates signaling molecules of the transforming growth factor beta pathway in ovarian carcinoma-derived RMG-I cells. Int J Oncol. 2012;40:1196–202.PubMed

24.

Zhuang H, Gao J, Hu Z, Liu J, Liu D, Lin B. Co-expression of Lewis y antigen with human epididymis protein 4 in ovarian epithelial carcinoma. PLoS One. 2013;8:e68994.CrossRefPubMedPubMedCentral

25.

Diaz-Montana JJ, Diaz-Diaz N. Development and use of the Cytoscape app GFD-Net for measuring semantic dissimilarity of gene networks. F1000 Res. 2014;3:142.

26.

Smaletz O, Diz MD, do Carmo CC, Sabbaga J, Cunha-Junior GF, Azevedo SJ, Maluf FC, Barrios CH, Costa RL, Fontana AG, Madrigal V, Wainstein AJ, Yeda FP, Alves VA, Moro AM, Blasbalg R, Scott AM, Hoffman EW. A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015;138:272–7.CrossRefPubMed

27.

Zhuang H, Tan M, Liu J, Hu Z, Liu D, Gao J, Zhu L, Lin B. Human epididymis protein 4 in association with annexin II promotes invasion and metastasis of ovarian cancer cells. Mol Cancer. 2014;13:243.CrossRefPubMedPubMedCentral

28.

Liu D, Liu J, Lin B, Liu S, Hou R, Hao Y, Liu Q, Zhang S, Iwamori M. Lewis y regulate cell cycle related factors in ovarian carcinoma cell RMG-I in vitro via ERK and Akt signaling pathways. Int J Mol Sci. 2012;13:828–39.CrossRefPubMedPubMedCentral

29.

Manocha GD, Mishra R, Sharma N, Kumawat KL, Basu A, Singh SK. Regulatory role of TRIM21 in the type-I interferon pathway in Japanese encephalitis virus-infected human microglial cells. J Neuroinflammation. 2014;11:24.CrossRefPubMedPubMedCentral

30.

Raheja R, Liu Y, Hukkelhoven E, Yeh N, Koff A. The ability of TRIM3 to induce growth arrest depends on ring-dependent E3 ligase activity. Biochem J. 2014;458:537–45.CrossRefPubMedPubMedCentral

31.

Bell JL, Malyukova A, Kavallaris M, Marshall GM, Cheung BB. TRIM16 inhibits neuroblastoma cell proliferation through cell cycle regulation and dynamic nuclear localization. Cell Cycle. 2013;12:889–98.CrossRefPubMedPubMedCentral

32.

Chen L, Chen DT, Kurtyka C, Rawal B, Fulp WJ, Haura EB, Cress WD. Tripartite motif containing 28 (Trim28) can regulate cell proliferation by bridging HDAC1/E2F interactions. J Biol Chem. 2012;287:40106–18.CrossRefPubMedPubMedCentral

33.

Zhou Z, Ji Z, Wang Y, Li J, Cao H, Zhu HH, Gao WQ. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology. 2014;147:1043–54.CrossRefPubMed

34.

Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M, Wang JB. TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 2015;10:e0142596.CrossRefPubMedPubMedCentral

35.

Yaguchi H, Okumura F, Takahashi H, Kano T, Kameda H, Uchigashima M, Tanaka S, Watanabe M, Sasaki H, Hatakeyama S. TRIM67 protein negatively regulates ras activity through degradation of 80K-H and induces neuritogenesis. J Biol Chem. 2012;287:12050–9.CrossRefPubMedPubMedCentral

36.

Feng Z, Lin B, Xu Y, Zhu L, Liu J, Gao J. Efficacy analysis of combining three comparative-omics profilings to screen candidate biological macromolecules. Mol Biol Rep. 2013;40:1861–6.CrossRefPubMed

37.

Kannan K, Kordestani GK, Galagoda A, Coarfa C, Yen L. Aberrant MUC1-TRIM46-KRTCAP2 chimeric RNAs in high-grade serous ovarian carcinoma. Cancers (Basel). 2015;7:2083–93.CrossRef

38.

Jardin F, Ruminy P, Bastard C, Tilly H. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol Biol (Paris). 2007;55:73–83.CrossRef

39.

Bentebibel SE, Schmitt N, Banchereau J, Ueno H. Human tonsil B-cell lymphoma 6 (BCL6)-expressing CD4+ T-cell subset specialized for B-cell help outside germinal centers. Proc Natl Acad Sci U S A. 2011;108:E488–97.CrossRefPubMedPubMedCentral

40.

Wang W, Hu S, Lu X, Young KH, Medeiros LJ. Triple-hit B-cell lymphoma with MYC, BCL2, AND BCL6 translocations/rearrangements: clinicopathologic features of 11 cases. Am J Surg Pathol. 2015;39:1132–9.CrossRefPubMed

41.

Wagner SD, Ahearne M, Ko Ferrigno P. The role of BCL6 in lymphomas and routes to therapy. Br J Haematol. 2011;152:3–12.CrossRefPubMed

42.

Jarosova M, Kriegova E, Schneiderova P, Fillerova R, Prochazka V, Mikesova M, Flodr P, Indrak K, Papajik T. A novel non-immunoglobulin (non-Ig)/BCL6 translocation in diffuse large B-cell lymphoma involving chromosome 10q11.21 loci and review on clinical consequences of BCL6 rearrangements. Pathol Oncol Res. 2015;22:233–43.CrossRefPubMed

43.

Hirata Y, Ogasawara N, Sasaki M, Mizushima T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, Kataoka H, Kamiya T, Higashiyama S, Joh T. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer. 2009;100:1320–9.CrossRefPubMedPubMedCentral

44.

Liang PI, Li CF, Chen LT, Sun DP, Chen TJ, Hsing CH, Hsu HP, Lin CY. BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2014;35:1417–26.CrossRefPubMed

45.

Wu Q, Liu X, Yan H, He YH, Ye S, Cheng XW, Zhu GL, Wu WY, Wang XN, Kong XJ, Xu XC, Lobie PE, Zhu T, Wu ZS. B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. BMC Cancer. 2014;14:418.CrossRefPubMedPubMedCentral

46.

Sena P, Mariani F, Benincasa M, De Leon MP, Di Gregorio C, Mancini S, Cavani F, Smargiassi A, Palumbo C, Roncucci L. Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis. Oncol Rep. 2014;31:103–10.PubMed

47.

Worsham MJ, Lu M, Chen KM, Stephen JK, Havard S, Schweitzer VP. Malignant and nonmalignant gene signatures in squamous head and neck cancer. J Oncol. 2012;2012:752860.CrossRefPubMedPubMedCentral

48.

Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 2015;365:190–200.CrossRefPubMed

49.

Shan W, Li J, Bai Y, Lu X. miR-339-5p inhibits migration and invasion in ovarian cancer cell lines by targeting NACC1 and BCL6. Tumour Biol. 2015;37:5203–11.CrossRefPubMed

50.

Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N, Xu XC. MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer. 2010;10:542.CrossRefPubMedPubMedCentral

51.

Wang YQ, Xu MD, Weng WW, Wei P, Yang YS, Du X. BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer. Am J Cancer Res. 2015;5:255–66.PubMed

52.

Racioppi L, Means AR. Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology. J Biol Chem. 2012;287:31658–65.CrossRefPubMedPubMedCentral

53.

Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM, Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011;30:2719–33.CrossRefPubMedPubMedCentral

54.

Lin F, Marcelo KL, Rajapakshe K, Coarfa C, Dean A, Wilganowski N, Robinson H, Sevick E, Bissig KD, Goldie LC, Means AR, York B. The camKK2/camKIV relay is an essential regulator of hepatic cancer. Hepatology. 2015;62:505–20.CrossRefPubMedPubMedCentral

55.

Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21–35.CrossRefPubMed

Titel: Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells
verfasst von: Song Gao
Liancheng Zhu
Huilin Feng
Zhenhua Hu
Shan Jin
Zuofei Song
Dawo Liu
Juanjuan Liu
Yingying Hao
Xiao Li
Bei Lin
Publikationsdatum: 30.05.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 9/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5080-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Gene expression profile analysis in response to α1,2-fucosyl transferase (FUT1) gene transfection in epithelial ovarian carcinoma cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2016

A convenient and effective strategy for the enrichment of tumor-initiating cell properties in prostate cancer cells

Galectin-8 is associated with recurrence and survival of patients with non-metastatic gastric cancer after surgery

Inhibition of protein methylesterase 1 decreased cancerous phenotypes in endometrial adenocarcinoma cell lines and xenograft tumor models

Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas

IGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes

Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie